Study reveals infection risks of common bowel disease drugs in seniors
NCT ID NCT07250815
First seen Dec 26, 2025 · Last updated May 15, 2026 · Updated 16 times
Summary
This study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to compare infection risks from three types of advanced treatments: ENTYVIO, TNF-alpha inhibitors, and ustekinumab. Researchers used existing Medicare claims data from 2016 to 2025 to track serious infections requiring hospitalization and non-serious infections. The goal was to understand which treatment might be safer for older patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Site
Cambridge, Massachusetts, 02142, United States
Conditions
Explore the condition pages connected to this study.